Stemtech Corporation (OTCQB:STEK), a US-based company announced this past Tuesday its planned merger (“Merger”) with Seacret Direct, LLC (“VIÁGO”) and now announces a proposal for a Reverse Takeover (RTO) of Eevia Health Plc (“Eevia”), a Finnish producer of bioactive organic Arctic plant extracts and nutraceuticals and has its common stock listed on the Swedish Spotlight Stock Market under the symbol “EEVIA”.
This strategic RTO marks a major milestone in the evolution of the combined companies, intending to create a vertically integrated health, wellness, and lifestyle entity that manufactures its own products and is positioned for significant growth in the global marketplace.
Reverse Takeover Structure and Valuation:
Under the proposed RTO, Eevia will acquire the assets and assume the liabilities of Stemtech and, upon completion of the Merger, VIÁGO by Eevia issuing new shares, resulting in Stemtech owning approximately 85% of Eevia, with the remaining 15% of the Eevia shares owned by its existing shareholders. The final valuation, share issuance, and terms are subject to conditions, including the negotiation of the definitive agreements, a third -party valuation, and the completion of the due diligence process.
Synergies and Strategic Rationale:
Stemtech and VIÁGO have identified Eevia’s advanced production facility in Kauhajoki, Finland, as a planned significant resource